{"organizations": [], "uuid": "06ab0383f3af5cca63eca8dbdf624d4953828491", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180308.html", "section_title": "Archive News &amp; Video for Thursday, 08 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-therapeuticsmd-announces-fda-accep/brief-therapeuticsmd-announces-fda-acceptance-of-new-drug-application-for-tx-001hr-idUSASB0C9KG", "country": "US", "domain_rank": 408, "title": "BRIEF-TherapeuticsMD Announces FDA Acceptance Of New Drug Application For Tx-001Hr", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.812, "site_type": "news", "published": "2018-03-09T05:42:00.000+02:00", "replies_count": 0, "uuid": "06ab0383f3af5cca63eca8dbdf624d4953828491"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-therapeuticsmd-announces-fda-accep/brief-therapeuticsmd-announces-fda-acceptance-of-new-drug-application-for-tx-001hr-idUSASB0C9KG", "ord_in_thread": 0, "title": "BRIEF-TherapeuticsMD Announces FDA Acceptance Of New Drug Application For Tx-001Hr", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "pdufa", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 8 (Reuters) - Therapeuticsmd Inc:\n* THERAPEUTICSMD ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION (NDA) AND PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE FOR TX-001HR\n* THERAPEUTICSMD INC - PDUFA TARGET ACTION DATE FOR COMPLETION OF FDAâ€™S REVIEW IS OCTOBER 28, 2018 FOR TX-001HR Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-09T05:42:00.000+02:00", "crawled": "2018-03-09T14:11:44.022+02:00", "highlightTitle": ""}